Shilpa Medicare Ltd
NSE:SHILPAMED

Watchlist Manager
Shilpa Medicare Ltd Logo
Shilpa Medicare Ltd
NSE:SHILPAMED
Watchlist
Price: 766.65 INR -1.48%
Market Cap: 75B INR
Have any thoughts about
Shilpa Medicare Ltd?
Write Note

Shilpa Medicare Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shilpa Medicare Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Shilpa Medicare Ltd
NSE:SHILPAMED
Current Portion of Long-Term Debt
â‚ą2.3B
CAGR 3-Years
-20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Current Portion of Long-Term Debt
â‚ą41.2B
CAGR 3-Years
256%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Current Portion of Long-Term Debt
â‚ą2.4B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
-17%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Current Portion of Long-Term Debt
â‚ą22B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Current Portion of Long-Term Debt
â‚ą16.5B
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Current Portion of Long-Term Debt
â‚ą231.2m
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Shilpa Medicare Ltd
Glance View

Market Cap
75B INR
Industry
Pharmaceuticals

Shilpa Medicare Ltd. engages in the manufacturing of pharmaceutical product and wind power generation. The company is headquartered in Raichur, Karnataka. The firm is engaged in manufacturing active pharmaceutical ingredients (APIs), formulation and development service. The company is focused on new drug delivery systems, peptides/biotech products and specialty chemicals. The Company’s product range include oncology and non-oncology APIs, oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. The company supplies oncology/non-oncology APIs and intermediates. Its oncology APIs products include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various regulated markets including USA, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India.

SHILPAMED Intrinsic Value
1 131.61 INR
Undervaluation 32%
Intrinsic Value
Price

See Also

What is Shilpa Medicare Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
2.3B INR

Based on the financial report for Sep 30, 2024, Shilpa Medicare Ltd's Current Portion of Long-Term Debt amounts to 2.3B INR.

What is Shilpa Medicare Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
-20%

Over the last year, the Current Portion of Long-Term Debt growth was -27%. The average annual Current Portion of Long-Term Debt growth rates for Shilpa Medicare Ltd have been -20% over the past three years .

Back to Top